Evolus Broadens Symatese Alliance to Bring Estyme HA Gels to Canada, Australia, and New Zealand
EOLS sits 57% above its 52-week low of $3.86.
Summary
Evolus has expanded its Symatese partnership to exclusively commercialize Estyme HA gels in Canada, Australia, and New Zealand, completing its injectable portfolio across all markets. The deal includes €920,000 upfront and up to €1.38 million in milestone payments, with commercialization expected in 2028.
Key Events · M&A and Partnerships · EOLS
-
License Territory Expansion
The amendment adds Canada, Australia, and New Zealand to the existing Symatese agreement, granting Evolus exclusive rights to commercialize the full Estyme HA gel line in these markets.
-
Financial Terms
Evolus will pay €920,000 in upfront signing payments and up to €1.38 million upon regulatory approvals. Symatese handles development and regulatory costs.
-
Commercialization Timeline
Pending regulatory approvals, Evolus expects to launch Estyme in the new territories in 2028.
-
Strategic Portfolio Completion
With this deal, Evolus now holds exclusive rights to both Nuceiva (neurotoxin) and Estyme (HA filler) in every market where it operates, targeting a combined $500 million annual addressable market.
Analysis · EOLS · Life Sciences
By amending its existing Symatese license, Evolus adds Canada, Australia, and New Zealand to its territory, rounding out its international injectable portfolio. The transaction calls for €920,000 in upfront payments and up to €1.38 million in regulatory milestones, with commercialization on track for 2028. This move aligns the Estyme HA gel franchise with the Nuceiva neurotoxin across all markets, targeting a combined $500 million annual addressable market. Leveraging existing commercial infrastructure, the expansion is expected to be accretive to international gross margins, further strengthening Evolus' competitive position in the global aesthetics market.
At the time of this filing, EOLS was trading at $6.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $398.4M. The 52-week trading range was $3.86 to $9.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.